AMWL — American Well Corporation

Summary of American Well Corporation (AMWL) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $249.3 million for FY 2025, down 22.1% year-over-year in Q4 to $55.3 million.
• Subscription Revenue: Constituted 53% of total revenue, up from 45% in 2024, reflecting a strategic shift towards higher-quality, predictable SaaS revenue.
• Adjusted EBITDA: Loss of $10.3 million in Q4, improved from a loss of $12.7 million in Q3 and a loss of $22.8 million in Q4 2024.
• Net Loss: $25.2 million in Q4, down from $30.7 million in Q3, marking a 43.5% year-over-year improvement.
• Cash Position: Ended the year with approximately $182 million in cash and marketable securities, with no debt.
• Cash Burn: Approximately $19 million in Q4.

2. Strategic Updates and Business Highlights

• Transformation Focus: AMWL has transitioned from a telehealth provider to a tech platform provider, emphasizing operational efficiency and consolidation in healthcare technology.
• Market Demand: There is a growing need for technology-enabled care solutions, driven by aging populations, rising healthcare costs, and clinician shortages.
• Contract Renewals: Successfully renewed over 15 payer contracts, including a significant three-year renewal with Elevance, which strengthens recurring revenue.
• AI Integration: Early benefits from AI integration were noted, with plans to enhance patient experience and operational efficiencies through AI in 2026.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $195 million and $205 million, with adjusted EBITDA losses projected between $24 million and $18 million.
• Q1 2026 Guidance: Revenue anticipated in the range of $48 million to $53 million, with adjusted EBITDA losses between $7 million and $5 million.
• Cash Flow Breakeven: The company aims to achieve cash flow breakeven from operations by Q4 2026.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Q4 revenue declined significantly due to contract changes and churn from prior years, particularly from the Defense Health Agency (DHA).
• Visit Volume Decline: Total platform visits fell 28.4% year-over-year, reflecting the impact of strategic divestitures and a focus on core markets.
• Competitive Pressures: The emergence of new AI companies in healthcare poses potential competitive risks, although AMWL believes its established infrastructure provides a competitive advantage.

5. Notable Q&A Insights

• Client Contracts: The majority of existing contracts are renewed, with only a few up for renewal in 2026, notably the DHA contract, which is expected to be renewed positively.
• Government Opportunities: AMWL is actively participating in government RFIs and RFPs, with a larger pipeline than ever, indicating potential for future revenue growth.
• AI Adoption: The integration of AI in clinical programs is seen as a significant opportunity, but challenges remain in managing multiple AI solutions within a regulated infrastructure.
• Long-term Growth: AMWL anticipates that the focus on a single tech platform will lead to higher-quality, stickier revenue and expects to benefit from same-store growth as clients increasingly adopt their technology.

Overall, American Well Corporation's Q4 2025 results reflect a year of significant transformation and strategic focus, with a clear path toward improved financial health and operational efficiency, despite facing challenges in revenue and market dynamics.